Study reveals the oncometabolite role of progesterone in advanced prostate cancer

NewsGuard 100/100 Score

In a study published in Cell Reports Medicine, a group of Chinese scientists revealed the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect as an aspect of prostate cancer treatment.

Androgen sustains the development of prostate cancer. Although androgen deprivation therapy and abiraterone eliminate the generation of androgen, disease progression is still inevitable.

In this study, a research team led by LI Zhenfei of the CAS Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences investigated alteration in the metabolomics of abiraterone-resistant patients and found that one metabolite-;progesterone-;increased significantly. Transient treatment with high doses of progesterone will activate multiple pathways to promote the proliferation of cancer cells. Long-term treatment with progesterone at a low dosage will increase the expression of GATA2, resulting in an irreversible alteration in the transcriptome that promotes disease progression.

They also investigated the metabolic pathway of progesterone. They identified the enzyme 3bHSD1 as a potential therapeutic target for eliminating the generation of progesterone. Specifically, they discovered that biochanin-A, an isoflavone rich in soy and other foods, is a 3bHSD1 inhibitor and suppresses prostate cancer development.

Based on the oncogenic effects of progesterone, plasma progesterone levels were found to be negatively correlated with the duration of abiraterone treatment. Thus, progesterone might be a potential predictive biomarker for abiraterone response and related clinical research is in progress.

In summary, the results of this study demonstrate that biochanin-A inhibits 3bHSD1, thus eliminating the oncogenic effects of progesterone and suppressing the development of prostate cancer.

WU Denglong's team from Tongji University-affiliated Tongji hospital and TANG Huiru's team from Fudan University also participated in the study.

Source:
Journal reference:

Hou, Z., et al. (2022) Inhibiting 3bHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Reports Medicine. doi.org/10.1016/j.xcrm.2022.100561.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Firefighters at increased risk of prostate cancer due to chemical exposures, study reveals